Last reviewed · How we verify
Dermatix
Dermatix is a Small molecule drug developed by University Hospital, Ghent. It is currently in Phase 1 development.
-
Baseline phase 1 → approval rate
+9.6pp
Industry-wide phase 1 drugs reach approval ~9.6% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).
| Regulator | Country | Likely year | Lag vs FDA |
|---|---|---|---|
| FDA | US | 2033–2036 | — |
| EMA | EU | 2034–2037 | +0.7 yr |
| MHRA | GB | 2034–2037 | +0.7 yr |
| Health Canada | CA | 2034–2038 | +0.9 yr |
| TGA | AU | 2034–2038 | +1.2 yr |
| PMDA | JP | 2034–2038 | +1.5 yr |
| NMPA | CN | 2035–2039 | +2.3 yr |
| MFDS | KR | 2034–2038 | +1.4 yr |
| CDSCO | IN | 2034–2039 | +1.8 yr |
| ANVISA | BR | 2035–2039 | +2.3 yr |
Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).
Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.
At a glance
| Generic name | Dermatix |
|---|---|
| Sponsor | University Hospital, Ghent |
| Modality | Small molecule |
| Therapeutic area | Dermatology |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- EGF-loaded Chitosan to Facilitate Healing and Prevent Scar Formation of Cesarean Wound (NA)
- Silicone Gel in the Treatment of Cleft Lip Scars (PHASE3)
- Silicone Gel to Improve Scar in Microtia Patients (PHASE4)
- Effect of Transparent, Self-drying Silicone Gel on the Treatment of Hypertrophic Abdominal Scars (PHASE4)
- Measurement and Comparison of the Occlusive and Hydrating Capacity of Three Silicone Gels and One Gel Cream (NA)
- An Investigator-blind Multi-center Prospective Study for the Efficacy and Safety of Silicon Gel (Dermatix) (PHASE4)
- Evaluation of the Efficacy, Tolerability, and Patient Acceptance of Dermatix Q for the Prevention and Management of Scars (PHASE4)
- Influence of a Silicone Gel (Dermatix®) on Thoracic Scar Formation After Harvesting of Autologous Rib Cartilage (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Dermatix CI brief — competitive landscape report
- Dermatix updates RSS · CI watch RSS
- University Hospital, Ghent portfolio CI
Frequently asked questions about Dermatix
What is Dermatix?
Who makes Dermatix?
What development phase is Dermatix in?
Related
- Manufacturer: University Hospital, Ghent — full pipeline
- Therapeutic area: All drugs in Dermatology
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing